Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 3,510 shares of Medpace stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.01, for a total transaction of $2,106,035.10. Following the sale, the chief executive officer owned 638,946 shares in the company, valued at approximately $383,373,989.46. This represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Medpace Stock Performance
Shares of NASDAQ MEDP opened at $585.49 on Thursday. The firm has a 50 day moving average price of $501.76 and a two-hundred day moving average price of $493.30. The stock has a market cap of $16.34 billion, a P/E ratio of 34.32, a price-to-earnings-growth ratio of 2.55 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the business earned $3.10 earnings per share. Medpace's revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts have commented on the company. Jefferies Financial Group downgraded Medpace from a "buy" rating to a "hold" rating and lifted their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. Mizuho upped their target price on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a report on Friday, July 24th. Finally, BMO Capital Markets increased their target price on shares of Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research report on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $584.18.
Read Our Latest Analysis on Medpace
Institutional Trading of Medpace
Large investors have recently bought and sold shares of the business. AQR Capital Management LLC lifted its stake in shares of Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company's stock valued at $758,061,000 after purchasing an additional 324,293 shares during the period. Wasatch Advisors LP grew its stake in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock worth $296,853,000 after purchasing an additional 116,354 shares during the period. Geode Capital Management LLC grew its stake in Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock worth $374,836,000 after purchasing an additional 24,625 shares during the period. Invesco Ltd. grew its stake in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company's stock worth $276,313,000 after purchasing an additional 85,517 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in Medpace by 8.3% in the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company's stock worth $242,337,000 after purchasing an additional 38,760 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.
About Medpace
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
